The Food and Drug Administration, in an attempt to ensure the safety of popular medicines, is partnering with one of the most prominent medical insurers in Massachusetts. It has awarded a contract for up to $150 million to Harvard Pilgrim Health Care Institute a collaboration between Harvard Pilgrim Health Care and Harvard Medical School to spearhead a program that sifts through billions of prescriptions and other electronic health care data to investigate issues with FDA-approved drugs. Richard Platt, head of the Department of Population Medicine and professor of population medicine, is quoted.
Trending News
Research Provides Clues to Spleen’s Role in Coronary Artery Disease
Genetic variants may drive visible changes in the spleen that contribute to heart disease
Patient Who Received Pig Kidney Becomes First To Progress to Human Kidney Transplant
Study shows xenotransplantation can serve as a bridge for patients with end-stage kidney disease
Pilots, Flight Attendants Have Greater Risk of Radiation-Related Cancer Death Than Other Professions
Findings support efforts to protect U.S. aircrews from cosmic radiation exposure